Corporate Governance - The company held two shareholder meetings in 2024, reviewing 16 agenda items, all of which were approved [2] - The company continuously improved its governance system, optimizing 26 governance rules to ensure scientific decision-making and operational compliance [2] Information Disclosure and Investor Protection - The company strictly adhered to relevant regulations for information disclosure, ensuring timely and accurate reporting of significant operational information [3] - Various communication channels were established with investors, including a hotline, dedicated email, and investor interaction platforms [3] Strategic Planning for 2025 - The company aims to implement its "One Elderly, One Child, One Woman" strategy, focusing on traditional Chinese medicine, chemical and biological preparations, and health products [4][5] - The strategy emphasizes enhancing product offerings in the elderly care, chronic disease, and women's health sectors [4][5] Organizational Structure and Marketing Strategy - The company plans to optimize its marketing organization, aligning market and sales systems to enhance user engagement [7] - A user-centered approach will be adopted, focusing on efficient service delivery and brand recognition [7] Production and Quality Assurance - The company will implement the "Ten Steps to Quality Medicine" to ensure product quality and efficacy [8] - Emphasis will be placed on lean and flexible production methods to enhance efficiency while maintaining high standards [8] Research and Development Strategy - The company will continue its "Buy, Improve, Collaborate, Research, and Substitute" strategy to enhance its R&D pipeline [9] - Focus will be on advancing in-progress products and exploring external expansion opportunities in core areas [9] Digital Transformation - The company is committed to advancing its digital transformation, creating a user-centered digital marketing ecosystem [10] - Integration of information technology and AI will be prioritized to enhance operational efficiency and management quality [10] Financial Overview - As of December 31, 2024, the company reported total assets of 582,587.60 million, with liabilities of 123,587.68 million and equity of 458,999.92 million [13] - The total revenue for 2024 was 337,704.77 million, with a net profit of 50,273.15 million [13]